
Overview
Pharmena is a life science company that develops innovative products and technologies based on the biological potential of 1-MNA, a naturally occurring molecule. Its work combines research, technology development and commercialization, with projects spanning healthy ageing, topical technologies and bioscience focused on 1-MNA.
Financials
Revenue history (in k)
Filing timeliness
Financial statements were filed on time, on average 38 days early. All were audited by a statutory auditor.
- 202501/07/2026
- 202401/07/2025
- 202315/04/2024
- 202226/06/2023
- 202105/07/2022
- 202029/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 2.78
- High
- PLN 2.78
- Low
- PLN 2.72
- Volume
- 787
- Avg. vol.
- 1.79K
- Market cap
- PLN 30.96M
- P/E ratio
- –
- EPS
- -PLN 0.27
- Shares outstanding
- 11.14M
- 52-week
- PLN 2.70 – 2.91
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLPHRMN00011
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 65.37k | USD -283.63k | USD -269.04k |
| Q1 2026 | USD 113.72k | USD -149.11k | USD -129.93k |
| Q4 2025 | USD 98.19k | USD -236.82k | USD -223.51k |
| Q3 2025 | USD 102.21k | USD -197.64k | USD -173.28k |
Results for Q3 2026:Nov 27, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
- Wholesale on a fee or contract basis (46.1)
Offer
- Healthy ageing products
- Topical technologies
- Bioscience products
- 1-MNA research
- Technology development
- Product commercialization
Websites
The sites are available in: Polish and English.
- pharmena.euPharmena SAWordPress 7.1ElementorGoogle AnalyticsGoogle Tag ManagerApache
- endotelio.euEndotelio – molekuła przyszłościWooCommerce 10.4WordPress 6.9ElementorGoogle AnalyticsGoogle Tag ManagerPPolylangApache
Trademarks
The company holds 6 active trademarks registered with the Polish Patent Office. 7 marks have expired or were not registered. The first mark was filed in 2008.
| Mark | Protected until | |
|---|---|---|
| 1-MNA | Jun 20, 2028 | |
| VETOEMVIT | Dec 12, 2027 | |
| pharmena | Mar 11, 2036 | |
| MENAREVIN (word) | Jul 18, 2034 | |
| MENAVITIN (word) | Jul 18, 2034 |
Authorized Representatives
Manner of representation
Joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations and sign on behalf of the company.
Supervisory board
Beneficial owners
Pharmena is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Capital group
The company belongs to the Pelion (Poland) group, which is its direct owner. The group has 10 companies, 1 of them abroad.
| Name | Ownership |
|---|---|
| 61.43% | |
Menavitin GmbH w likwidacji | 13% |
| 73% |
Bank accounts
Registered as a VAT taxpayer on 2002-12-30.
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Sep 11, 2012 | Commercial Companies Code notice | |
| Aug 29, 2012 | Commercial Companies Code notice | |
| May 31, 2010 | Shareholders' meeting convened | |
| May 10, 2010 | Shareholders' meeting convened |
Public aid
6 public aid cases recorded, with a total value of $296,872.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 16, 2021 | Other crisis aid | $76,971$76,971 | Polski Fundusz Rozwoju S.A. | |
| Feb 9, 2021 | Other crisis aid | $190.1K$190,059 | Polski Fundusz Rozwoju S.A. | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $10,398$10,398 | Prezes Zakładu Ubezpieczeń Społecznych |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o. | $969,037.30 | kmptm.pl | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Human Biome S.A. | $583,508.16 | human-biome.com | ||
| Uvera S.A. | $504,076.78 | uvera.eu | ||
| Forvite P.S.A. | $468,502.70 | forvite.com | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Protexture sp. z o.o. | $339,354.50 | protexture.pl | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Nanosanguis S.A. | $192,701.50 | nanosanguis.com | ||
| Nexbio sp. z o.o. | $186,582.40 | nexbio.pl |
Change history
| Date | Event | |
|---|---|---|
| 2023-09-05 | Address change (Wólczańska 178, 90-530, Łódź → Ul. Gdańska 47/49, 90-729, Łódź) | |
| 2021-03-08 | Share capital increase (1,098,475.80 PLN → 1,113,775.80 PLN) | |
| 2019-06-12 | Share capital increase (879,505.20 PLN → 1,098,475.80 PLN) | |
| 2015-07-24 | PKD change (Removed: 10 codes) | |
| 2013-07-25 | Share capital increase (703,604.20 PLN → 879,505.20 PLN) |
FAQ
Last updated: 2026-07-04
